Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback